市場調査レポート

商品コード

1727110

骨転移治療の世界市場：タイプ別、治療別、主要ブランド別、地域別、機会、予測、2018年～2032年

Bone Metastasis Treatment Market Assessment, By Type [Osteolytic, Osteoblastic, Mixed], By Treatment [Medication, Surgery], By Major Brands [Xgeva, Zometa, Xofigo, Others], By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年05月19日
発行: Market Xcel - Markets and Data
ページ情報: 英文 259 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 653,760円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 828,096円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,191,296円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=145.28円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の骨転移治療の市場規模は、2025年～2032年の予測期間中に8.40％のCAGRで拡大し、2024年の193億8,000万米ドルから2032年には369億4,000万米ドルに成長すると予測されています。この市場を牽引しているのは、骨転移のリスクを高めるがんの世界的な有病率の上昇です。放射性医薬品や標的生物製剤などの治療技術の進歩により、患者の転帰が改善され、治療の選択肢が広がっています。さらに、小児がん患者の増加と北米のイノベーション主導型ヘルスケアインフラが市場成長に大きく寄与しています。

例えば、2024年11月、骨や軟部組織に影響を及ぼす転移性乳がんに対する局所投与による革新的な治療法の創製に専念する臨床段階にある非公開バイオ医薬品会社Zetagen Therapeutics, Inc.は、第2a相試験で最初の患者2人の登録を発表しました。本試験では、脊髄転移性溶解性乳がん病変に対するZetaMet（Zeta-BC-003）の有効性を評価します。

当レポートでは、世界の骨転移治療市場について調査し、市場の概要とともに、タイプ別、治療別、主要ブランド別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

市場規模分析と予測
市場シェア分析と予測
- タイプ別
  - 骨溶解性
  - 骨芽細胞
  - 混合
- 治療別
  - 投薬
  - 手術
- 主要ブランド別
  - Xgeva
  - Zometa
  - Xofigo
  - その他
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
2024年の市場マップ分析

第6章北米の骨転移治療市場の見通し、2018年～2032年

市場規模分析と予測
市場シェア分析と予測
国別市場評価
- 米国
- カナダ
- メキシコ

第7章欧州の骨転移治療市場の見通し、2018年～2032年

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第8章アジア太平洋の骨転移治療市場の見通し、2018年～2032年

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第9章南米の骨転移治療市場の見通し、2018年～2032年

ブラジル
アルゼンチン

第10章中東・アフリカの骨転移治療市場の見通し、2018年～2032年

サウジアラビア
アラブ首長国連邦
南アフリカ

第11章需要供給分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章 PESTLE分析

第15章価格分析

第16章市場力学

市場の促進要因
市場の課題

第17章市場動向と発展

第18章規制枠組みとイノベーション

規制当局の承認
臨床試験

第19章特許の情勢

第20章ケーススタディ

第21章競合情勢

市場リーダートップ5の競合マトリックス
参入企業トップ5のSWOT分析
市場の主要企業トップ10の情勢
- Bayer AG
- Amgen Inc.
- F. Hoffmann-La Roche Ltd
- Pfizer Inc.
- Merck & Co., Inc.
- Novartis AG
- Pharmalucence Inc.
- Koninklijke Philips N.V.
- Eli Lilly and Company
- Medtronic PLC

第22章戦略的提言

第23章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 3. Global Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 4. Global Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 5. Global Bone Metastasis Treatment Market Share (%), By Region, 2018-2032F
Figure 6. North America Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 7. North America Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 8. North America Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 9. North America Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 10. North America Bone Metastasis Treatment Market Share (%), By Country, 2018-2032F
Figure 11. United States Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 12. United States Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 13. United States Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 14. United States Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 15. Canada Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 16. Canada Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 17. Canada Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 18. Canada Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 19. Mexico Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 20. Mexico Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 21. Mexico Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 22. Mexico Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 23. Europe Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 24. Europe Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 25. Europe Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 26. Europe Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 27. Europe Bone Metastasis Treatment Market Share (%), By Country, 2018-2032F
Figure 28. Germany Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 29. Germany Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 30. Germany Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 31. Germany Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 32. France Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 33. France Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 34. France Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 35. France Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 36. Italy Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 37. Italy Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 38. Italy Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 39. Italy Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 40. United Kingdom Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 41. United Kingdom Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 42. United Kingdom Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 43. United Kingdom Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 44. Russia Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 45. Russia Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 46. Russia Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 47. Russia Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 48. Netherlands Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 49. Netherlands Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 50. Netherlands Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 51. Netherlands Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 52. Spain Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 53. Spain Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 54. Spain Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 55. Spain Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 56. Turkey Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 57. Turkey Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 58. Turkey Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 59. Turkey Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 60. Poland Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 61. Poland Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 62. Poland Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 63. Poland Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 64. South America Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 65. South America Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 66. South America Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 67. South America Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 68. South America Bone Metastasis Treatment Market Share (%), By Country, 2018-2032F
Figure 69. Brazil Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 70. Brazil Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 71. Brazil Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 72. Brazil Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 73. Argentina Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 74. Argentina Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 75. Argentina Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 76. Argentina Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 77. Asia-Pacific Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 78. Asia-Pacific Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 79. Asia-Pacific Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 80. Asia-Pacific Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 81. Asia-Pacific Bone Metastasis Treatment Market Share (%), By Country, 2018-2032F
Figure 82. India Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 83. India Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 84. India Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 85. India Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 86. China Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 87. China Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 88. China Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 89. China Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 90. Japan Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 91. Japan Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 92. Japan Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 93. Japan Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 94. Australia Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 95. Australia Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 96. Australia Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 97. Australia Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 98. Vietnam Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 99. Vietnam Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 100. Vietnam Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 101. Vietnam Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 102. South Korea Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 103. South Korea Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 104. South Korea Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 105. South Korea Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 106. Indonesia Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 107. Indonesia Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 108. Indonesia Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 109. Indonesia Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 110. Philippines Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 111. Philippines Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 112. Philippines Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 113. Philippines Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 114. Middle East & Africa Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 115. Middle East & Africa Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 116. Middle East & Africa Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 117. Middle East & Africa Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 118. Middle East & Africa Bone Metastasis Treatment Market Share (%), By Country, 2018-2032F
Figure 119. Saudi Arabia Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 120. Saudi Arabia Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 121. Saudi Arabia Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 122. Saudi Arabia Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 123. UAE Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 124. UAE Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 125. UAE Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 126. UAE Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 127. South Africa Bone Metastasis Treatment Market, By Value, In USD Billion, 2018-2032F
Figure 128. South Africa Bone Metastasis Treatment Market Share (%), By Type, 2018-2032F
Figure 129. South Africa Bone Metastasis Treatment Market Share (%), By Treatment, 2018-2032F
Figure 130. South Africa Bone Metastasis Treatment Market Share (%), By Major Brands, 2018-2032F
Figure 131. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 132. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 133. By Major Brands Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX13148

Global bone metastasis treatment market is projected to witness a CAGR of 8.40% during the forecast period 2025-2032, growing from USD 19.38 billion in 2024 to USD 36.94 billion in 2032. The market is driven by the growing global prevalence of cancer, which increases the risk of bone metastases. Advances in treatment technologies, such as radiopharmaceuticals and targeted biologics, are improving patient outcomes and expanding therapeutic options. Furthermore, rising pediatric cancer cases and North America's innovation-led healthcare infrastructure are contributing significantly to market growth.

For instance, in November 2024, Zetagen Therapeutics, Inc., a private biopharmaceutical company in the clinical stage dedicated to creating innovative therapies through local administration for metastatic breast cancer affecting bone and soft tissues, announced the enrollment of the first two patients in phase 2a study. This study will assess the efficacy of ZetaMet (Zeta-BC-003) in treating spinal metastatic lytic breast cancer lesions.

Rising Global Cancer Burden Fuels Demand for Bone Metastasis Treatment

The increasing prevalence of primary cancers, particularly breast cancer, prostate cancer, and lung cancer, is a significant driver of the bone metastasis treatment market. As these cancers frequently metastasize to bones, the need for early diagnosis and effective treatment of skeletal-related complications is escalating. Advanced imaging modalities and improvements in diagnostics have enabled earlier detection of bone metastases, leading to better therapeutic outcomes. Furthermore, increasing awareness of palliative care and the rising emphasis on quality of life for advanced cancer patients have encouraged the use of bone-targeted therapies such as bisphosphonates and RANK ligand inhibitors. Pharmaceutical companies are also actively investing in innovative drug development to enhance effectiveness and reduce side effects of current treatments. For instance, the American Cancer Society projects that in 2025, there will be approximately 3,770 new cases of primary bone and joint cancers, comprising 2,150 cases in males and 1,620 in females, along with an estimated 2,190 fatalities, including 1,240 in males and 950 in females. This data encompasses both pediatric and adult populations. Primary bone cancers, which originate in the bones, are relatively rare, representing less than 1% of all cancer cases. In adults, cancers that metastasize bones from other sites are significantly more prevalent than primary bone cancers.

Technological Advancements in Targeted Therapies and Radiopharmaceuticals

Ongoing innovations in targeted therapies and radiopharmaceuticals significantly reshape the bone metastasis treatment landscape. Radiopharmaceuticals like Xofigo (radium-223 dichloride) offer more focused approaches, delivering localized radiation therapy that spares healthy tissue and minimizes systemic toxicity. The emergence of combination therapies-pairing bone-targeted agents with immunotherapies or chemotherapy-is enhancing efficacy in managing skeletal metastases. Additionally, artificial intelligence and precision medicine aid in patient stratification and personalized treatment plans, increasing success rates. These advancements not only improve clinical outcomes but also lower the burden of skeletal-related events such as fractures, spinal compression, and pain. Companies are actively launching and refining novel drugs to maintain a competitive advantage. For instance, in March 2023, a team of researchers from the University of Sheffield and the University of East Anglia introduced a novel medication named CADD522 to treat individuals with primary bone cancers. This medication demonstrated a 50% improvement in survival rates in preclinical studies.

Rising Incidences of Bone Metastasis in Pediatric Oncology Accelerates Treatment Needs

Although bone metastasis is more common in adults, its occurrence in pediatric cancers such as neuroblastoma, Ewing sarcoma, and osteosarcoma is growing attention. As pediatric oncology sees rising case detection due to improved diagnostics and awareness, the need for age-specific bone metastasis treatment is becoming critical. Children with metastatic cancer often face rapid disease progression and complications involving bones, demanding early and aggressive intervention. The treatment approach in pediatric cases emphasizes minimizing long-term toxicity while effectively managing skeletal-related complications. Drug developers are now focusing on pediatric clinical trials and safety profiles tailored for children.

North America Maintains Market Leadership

North America dominates the global bone metastasis treatment market due to its high cancer burden, advanced healthcare infrastructure, and strong pharmaceutical R&D ecosystem. The U.S., in particular, reports many cancer cases that often progress to metastatic stages, necessitating robust bone-targeted interventions. Favorable reimbursement policies and fast-track regulatory approvals further facilitate the availability and adoption of advanced therapies. Moreover, patient awareness, widespread access to oncology specialists, and a strong network of cancer treatment centers support proactive treatment. The region is also a hub for clinical trials and drug innovation, contributing significantly to new approvals. The FDA has granted approval for Wyost/Jubbonti (denosumab-bddz; GP2411) in March 2024, marking it as the first biosimilar to the reference drugs Xgeva/Prolia (denosumab) in the United States. This medication will be utilized for the treatment of osteoporosis and hypercalcemia, in addition to preventing skeletal-related events linked to bone metastases from solid tumors.

Future Market Scenario (2025-2032F)

The global bone metastasis treatment market is poised for significant growth driven by the rising global cancer burden and growing awareness of metastatic complications. As cancer survival rates improve due to early diagnosis and advanced treatments, the number of patients at risk for bone metastases is also increasing. Continuous innovations in radiopharmaceuticals, targeted biologics, and minimally invasive surgical techniques enhance treatment efficacy and patient outcomes. Additionally, rising investments in oncology research, increasing use of AI in treatment planning, and growing clinical focus on pediatric metastatic cases are expected to expand market potential. North America will continue to dominate due to high healthcare spending and innovation, while emerging economies in Asia-Pacific are projected to offer substantial opportunities through improved access to oncology care.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of bone metastasis treatment and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, in November 2023, Telix proposed an acquisition of Qsam Biosciences for USD 33.1 million, aiming to enhance its product portfolio with a phase 1 radiopharmaceutical for bone cancer. This medication aids in the treatment of cancer that has spread to the bone from various organs, including the breast, lung, and prostate.

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Bone Metastasis Treatment Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Type
  - 5.2.1.1. Osteolytic
  - 5.2.1.2. Osteoblastic
  - 5.2.1.3. Mixed
- 5.2.2. By Treatment
  - 5.2.2.1. Medication
  - 5.2.2.2. Surgery
- 5.2.3. By Major Brands
  - 5.2.3.1. Xgeva
  - 5.2.3.2. Zometa
  - 5.2.3.3. Xofigo
  - 5.2.3.4. Others
- 5.2.4. By Region
  - 5.2.4.1. North America
  - 5.2.4.2. Europe
  - 5.2.4.3. Asia-Pacific
  - 5.2.4.4. South America
  - 5.2.4.5. Middle East and Africa
- 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
- 5.3.1. By Type
- 5.3.2. By Treatment
- 5.3.3. By Major Brands
- 5.3.4. By Region

6. North America Bone Metastasis Treatment Market Outlook, 2018-2032F

6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
6.2. Market Share Analysis & Forecast
- 6.2.1. By Type
  - 6.2.1.1. Osteolytic
  - 6.2.1.2. Osteoblastic
  - 6.2.1.3. Mixed
- 6.2.2. By Treatment
  - 6.2.2.1. Medication
  - 6.2.2.2. Surgery
- 6.2.3. By Major Brands
  - 6.2.3.1. Xgeva
  - 6.2.3.2. Zometa
  - 6.2.3.3. Xofigo
  - 6.2.3.4. Others
- 6.2.4. By Country Share
  - 6.2.4.1. United States
  - 6.2.4.2. Canada
  - 6.2.4.3. Mexico
6.3. Country Market Assessment
- 6.3.1. United States Bone Metastasis Treatment Market Outlook, 2018-2032F*
  - 6.3.1.1. Market Size Analysis & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share Analysis & Forecast
    - 6.3.1.2.1. By Type
      - 6.3.1.2.1.1. Osteolytic
      - 6.3.1.2.1.2. Osteoblastic
      - 6.3.1.2.1.3. Mixed
    - 6.3.1.2.2. By Treatment
      - 6.3.1.2.2.1. Medication
      - 6.3.1.2.2.2. Surgery
    - 6.3.1.2.3. By Major Brands
      - 6.3.1.2.3.1. Xgeva
      - 6.3.1.2.3.2. Zometa
      - 6.3.1.2.3.3. Xofigo
      - 6.3.1.2.3.4. Others
- 6.3.2. Canada
- 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Bone Metastasis Treatment Market Outlook, 2018-2032F

7.1. Germany
7.2. France
7.3. Italy
7.4. United Kingdom
7.5. Russia
7.6. Netherlands
7.7. Spain
7.8. Turkey
7.9. Poland

8. Asia-Pacific Bone Metastasis Treatment Market Outlook, 2018-2032F

8.1. India
8.2. China
8.3. Japan
8.4. Australia
8.5. Vietnam
8.6. South Korea
8.7. Indonesia
8.8. Philippines

9. South America Bone Metastasis Treatment Market Outlook, 2018-2032F

9.1. Brazil
9.2. Argentina

10. Middle East and Africa Bone Metastasis Treatment Market Outlook, 2018-2032F

10.1. Saudi Arabia
10.2. UAE
10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

16.1. Market Drivers
16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

18.1. Regulatory Approvals
18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

21.1. Competition Matrix of Top 5 Market Leaders
21.2. SWOT Analysis for Top 5 Players
21.3. Key Players Landscape for Top 10 Market Players
- 21.3.1. Bayer AG
  - 21.3.1.1. Company Details
  - 21.3.1.2. Key Management Personnel
  - 21.3.1.3. Products and Services
  - 21.3.1.4. Financials (As Reported)
  - 21.3.1.5. Key Market Focus and Geographical Presence
  - 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
- 21.3.2. Amgen Inc.
- 21.3.3. F. Hoffmann-La Roche Ltd
- 21.3.4. Pfizer Inc.
- 21.3.5. Merck & Co., Inc.
- 21.3.6. Novartis AG
- 21.3.7. Pharmalucence Inc.
- 21.3.8. Koninklijke Philips N.V.
- 21.3.9. Eli Lilly and Company
- 21.3.10. Medtronic PLC

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

骨転移治療の世界市場：タイプ別、治療別、主要ブランド別、地域別、機会、予測、2018年～2032年

Bone Metastasis Treatment Market Assessment, By Type [Osteolytic, Osteoblastic, Mixed], By Treatment [Medication, Surgery], By Major Brands [Xgeva, Zometa, Xofigo, Others], By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の骨転移治療市場の見通し、2018年～2032年

第6章 北米の骨転移治療市場の見通し、2018年～2032年

第7章 欧州の骨転移治療市場の見通し、2018年～2032年

第8章 アジア太平洋の骨転移治療市場の見通し、2018年～2032年

第9章 南米の骨転移治療市場の見通し、2018年～2032年

第10章 中東・アフリカの骨転移治療市場の見通し、2018年～2032年

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析